1)独立行政法人医薬品医療機器総合機構ホームページ:治験計画届出件数 https://www.pmda.go.jp/review-services/trials/0014.html(2018年3月閲覧)
2)Fletcher RH, et al:Clinical Epidemiology;the essentials, 5th ed, Lippincott Williams & Wilkins, Philadelphia, 2012
3)Green S, et al(eds):Clinical Trials in Oncology, 3rd ed, CRC Press, Boca Raton, 2012
4)Tsukasaki K, et al:Lymphoma study group of JCOG. Jpn J Clin Oncol 42:85-95, 2012
5)DeVita VT Jr., et al(eds):Cancer;principles and practice of oncology, 10th ed, Lippincott Williams & Wilkins, Philadelphia, 2014
6)Swerdlow SH, et al(eds):WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, IARC Press, Lyon, 2016
7)Makita S, Tobinai K:Targeting enhancer-of-zeste-homolog-2 with tazemetostat. Lancet Oncol, 2018 in press
8)Jurczak W, et al:Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol, 2018 in press[Epub ahead of print]
9)Makita S, et al:Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108:1109-1118, 2017
10)国立研究開発法人国立がん研究センターホームページ:国内で薬事法上未承認・適応外である医薬品について https://www.ncc.go.jp/jp/senshiniryo/iyakuhin/index.html(2018年3月閲覧)